TrialPanorama/Dataset huggingface dataset:
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Phase 3 Multicenter, Randomized, Controlled, Clinical Trial to Assess the Safety and Efficacy of Injectable Paromomycin in Patients With Visceral Leishmaniasis
Brief Summary: Symptomatic Visceral Leishmaniasis(VL)is fatal; Due to the increasing resistance to standard therapy with antimonials, there is a need for new safe, efficacious, low-cost therapies for the treatment of VL. Paromomycin is an off-patent aminoglycoside antibiotic with anti-leishmaniasis activity. This study will test the safety and efficacy of paromomycin in the treatment of patients with VL in India.


Options:
A: Arm Label: WR 279,396; Type: EXPERIMENTAL; Interventions: Drug: WR 279,396 | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: WR 279,396; Assigned to Arm(s): WR 279,396 | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
B: Arm Label: WR 279,396 Topical Treament; Type: EXPERIMENTAL; Interventions: Drug: WR 279,396 topical cream | Arm Label: Paromomycin Alone Topical treatment; Type: EXPERIMENTAL; Interventions: Drug: Paromomycin Alone topical cream | Arm Label: Vehicle Placebo Cream; Type: PLACEBO_COMPARATOR; Interventions: Drug: Vehicle placebo cream | Intervention Type: DRUG; Name: WR 279,396 topical cream; Assigned to Arm(s): WR 279,396 Topical Treament | Intervention Type: DRUG; Name: Paromomycin Alone topical cream; Assigned to Arm(s): Paromomycin Alone Topical treatment | Intervention Type: DRUG; Name: Vehicle placebo cream; Assigned to Arm(s): Vehicle Placebo Cream
C: Intervention Type: DRUG; Name: Paromomycin sulfate; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: Amphotericin B; Assigned to Arm(s): N/A
D: Arm Label: Sodium stibogluconate intravenous; Type: ACTIVE_COMPARATOR; Interventions: Drug: Sodium stibogluconate (Pentostam) | Arm Label: ThermoMed device; Type: EXPERIMENTAL; Interventions: Device: ThermoMed | Intervention Type: DRUG; Name: Sodium stibogluconate (Pentostam); Assigned to Arm(s): Sodium stibogluconate intravenous | Intervention Type: DEVICE; Name: ThermoMed; Assigned to Arm(s): ThermoMed device

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: CONSTATRE: Risperdal Consta Trial Of Relapse Prevention And Effectiveness
Brief Summary: The purpose of this study is to investigate whether a long-acting injectable formulation of risperidone provides better effectiveness over 2 years, as measured by the time to relapse, compared with quetiapine tablets in a routine psychiatric care setting. Aripiprazole will be investigated in a descriptive manner.


Options:
A: Arm Label: 001; Type: EXPERIMENTAL; Interventions: Drug: Risperidone Long Acting Injectable (LAI) | Arm Label: 002; Type: ACTIVE_COMPARATOR; Interventions: Drug: Quetiapine | Arm Label: 003; Type: OTHER; Interventions: Drug: Aripiprazole | Intervention Type: DRUG; Name: Aripiprazole; Assigned to Arm(s): 003 | Intervention Type: DRUG; Name: Risperidone Long Acting Injectable (LAI); Assigned to Arm(s): 001 | Intervention Type: DRUG; Name: Quetiapine; Assigned to Arm(s): 002
B: Arm Label: Risperidone Long Acting; Type: EXPERIMENTAL; Interventions: Drug: Risperidone Long Acting | Arm Label: Oral Risperidone; Type: ACTIVE_COMPARATOR; Interventions: Drug: oral risperidone | Intervention Type: DRUG; Name: Risperidone Long Acting; Assigned to Arm(s): Risperidone Long Acting | Intervention Type: DRUG; Name: oral risperidone; Assigned to Arm(s): Oral Risperidone
C: Intervention Type: DRUG; Name: risperidone; Assigned to Arm(s): N/A
D: Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Drug: quetiapine, risperidone | Intervention Type: DRUG; Name: quetiapine, risperidone; Assigned to Arm(s): 1

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Treatment of Severe Alzheimer's Disease in a Residential Home, Nursing Home, or Geriatric Residential Setting: Evaluation of Efficacy and Safety of Galantamine Hydrobromide in a Randomised, Doubleblind, Placebo-Controlled Study.
Brief Summary: The purpose of this study is to assess the effectiveness and safety of galantamine hydrobromide treatment in patients with severe Alzheimer's disease.


Options:
A: Intervention Type: DRUG; Name: galantamine hydrobromide; Assigned to Arm(s): N/A
B: Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Arm Label: Memantine ER; Type: ACTIVE_COMPARATOR; Interventions: Drug: memantine ER | Intervention Type: DRUG; Name: memantine ER; Assigned to Arm(s): Memantine ER | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
C: Arm Label: Decision support; Type: EXPERIMENTAL; Interventions: Other: Feeding Options in Dementia Decision Aid | Arm Label: Control; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: OTHER; Name: Feeding Options in Dementia Decision Aid; Assigned to Arm(s): Decision support
D: Arm Label: Galantamine; Type: EXPERIMENTAL; Interventions: Drug: Galantamine | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Galantamine; Assigned to Arm(s): Galantamine | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Treatment of Severe Alzheimer's Disease in a Residential Home, Nursing Home, or Geriatric Residential Setting: Evaluation of Efficacy and Safety of Galantamine Hydrobromide in a Randomised, Doubleblind, Placebo-Controlled Study.
Brief Summary: The purpose of this study is to assess the effectiveness and safety of galantamine hydrobromide treatment in patients with severe Alzheimer's disease.


Options:
A: Arm Label: A; Type: PLACEBO_COMPARATOR; Interventions: Drug: Risperidone, Drug: Escitalopram, Drug: Citalopram, Drug: Sertraline, Drug: Paroxetine | Intervention Type: DRUG; Name: Risperidone; Assigned to Arm(s): A | Intervention Type: DRUG; Name: Escitalopram; Assigned to Arm(s): A | Intervention Type: DRUG; Name: Citalopram; Assigned to Arm(s): A | Intervention Type: DRUG; Name: Sertraline; Assigned to Arm(s): A | Intervention Type: DRUG; Name: Paroxetine; Assigned to Arm(s): A
B: Arm Label: Decision support; Type: EXPERIMENTAL; Interventions: Other: Feeding Options in Dementia Decision Aid | Arm Label: Control; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: OTHER; Name: Feeding Options in Dementia Decision Aid; Assigned to Arm(s): Decision support
C: Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Arm Label: Memantine ER; Type: ACTIVE_COMPARATOR; Interventions: Drug: memantine ER | Intervention Type: DRUG; Name: memantine ER; Assigned to Arm(s): Memantine ER | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
D: Intervention Type: DRUG; Name: galantamine hydrobromide; Assigned to Arm(s): N/A

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Calcipotriol Plus Betamethasone Dipropionate Gel Compared to Betamethasone Dipropionate in the Gel Vehicle and Calcipotriol in the Gel Vehicle in Scalp Psoriasis
Brief Summary: The purpose of the study is to evaluate whether once daily topical treatment for up to 8 weeks of calcipotriol 50 mcg/g plus betamethasone 0.5 mg/g (as dipropionate) gel is safe and more effective than betamethasone 0.5 mg/g (as dipropionate) in the gel vehicle and calcipotriol 50 mcg/g in the gel vehicle in patients with scalp psoriasis.

The primary response criterion is the number of patients with absence of disease and very mild disease after 8 weeks of treatment.


Options:
A: Arm Label: U0267 Foam; Type: EXPERIMENTAL; Interventions: Drug: U0267 | Arm Label: Vehicle foam; Type: PLACEBO_COMPARATOR; Interventions: Drug: Vehicle | Intervention Type: DRUG; Name: U0267; Assigned to Arm(s): U0267 Foam | Intervention Type: DRUG; Name: Vehicle; Assigned to Arm(s): Vehicle foam
B: Intervention Type: DRUG; Name: Calcipotriol plus betamethasone dipropionate (LEO80185 gel); Assigned to Arm(s): N/A
C: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: LCD | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Drug: calcipotriol | Intervention Type: DRUG; Name: LCD; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: calcipotriol; Assigned to Arm(s): 2
D: Arm Label: U0267 foam; Type: EXPERIMENTAL; Interventions: Drug: U0267 Foam | Arm Label: Vehicle foam; Type: PLACEBO_COMPARATOR; Interventions: Drug: Vehicle foam | Intervention Type: DRUG; Name: U0267 Foam; Assigned to Arm(s): U0267 foam | Intervention Type: DRUG; Name: Vehicle foam; Assigned to Arm(s): Vehicle foam

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: The Statin Choice Decision Aid and Its Effects on Statin Decisions in Patients With Type 2 Diabetes Mellitus. A Clustered Randomized Trial
Brief Summary: Background- Statins are a safe and effective therapy to reduce cardiovascular risk in patients with type 2 diabetes; however some patients are not prescribed statins, others do not take it even after being prescribed, and others stop therapy prematurely. Lack of knowledge or misinformation about statins may be responsible for inadequate statin use.

Objective- To test the hypothesis that a formal, structured decision aid could correct deficiencies in the current decision-making process, increase statin use, and improve outcomes in patients with type 2 diabetes.

Methods - The investigators will develop a decision aid called STATIN CHOICE and will pilot its efficacy in a blinded randomized controlled trial enrolling 98 type 2 diabetes patients.

Outcomes- Primary outcomes: adherence to the decision to use or not to use statins three months after using STATIN CHOICE. Secondary outcomes: acceptability of STATIN CHOICE, knowledge about options, satisfaction with decisions, decisional conflict, encounter duration, and quality of life.

Expected results- The investigators anticipate that this work will yield an effective and innovative decision aid for statin use in type 2 diabetes patients. STATIN CHOICE, along with a detailed users manual, will be directly applicable in clinical practice. Data and experience from this project will inform the planning and conduct of a randomized multicenter trial of the effectiveness of STATIN CHOICE in diverse practice settings.

Significance- Patient participation in decision-making resulting in informed treatment decisions, as proposed in this study, will likely lead to improved quality of decision-making, more appropriate use of statins, and improved patient outcomes.


Options:
A: Intervention Type: OTHER; Name: informational intervention; Assigned to Arm(s): N/A | Intervention Type: OTHER; Name: questionnaire administration; Assigned to Arm(s): N/A | Intervention Type: OTHER; Name: survey administration; Assigned to Arm(s): N/A
B: Intervention Type: DEVICE; Name: Decision Aid Statin Choice; Assigned to Arm(s): N/A
C: Intervention Type: BEHAVIORAL; Name: Decision Aid; Assigned to Arm(s): N/A
D: Arm Label: ADAPT tool; Type: EXPERIMENTAL; Interventions: Behavioral: ADAPT tool | Arm Label: Control; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: ADAPT tool; Assigned to Arm(s): ADAPT tool

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: The Statin Choice Decision Aid and Its Effects on Statin Decisions in Patients With Type 2 Diabetes Mellitus. A Clustered Randomized Trial
Brief Summary: Background- Statins are a safe and effective therapy to reduce cardiovascular risk in patients with type 2 diabetes; however some patients are not prescribed statins, others do not take it even after being prescribed, and others stop therapy prematurely. Lack of knowledge or misinformation about statins may be responsible for inadequate statin use.

Objective- To test the hypothesis that a formal, structured decision aid could correct deficiencies in the current decision-making process, increase statin use, and improve outcomes in patients with type 2 diabetes.

Methods - The investigators will develop a decision aid called STATIN CHOICE and will pilot its efficacy in a blinded randomized controlled trial enrolling 98 type 2 diabetes patients.

Outcomes- Primary outcomes: adherence to the decision to use or not to use statins three months after using STATIN CHOICE. Secondary outcomes: acceptability of STATIN CHOICE, knowledge about options, satisfaction with decisions, decisional conflict, encounter duration, and quality of life.

Expected results- The investigators anticipate that this work will yield an effective and innovative decision aid for statin use in type 2 diabetes patients. STATIN CHOICE, along with a detailed users manual, will be directly applicable in clinical practice. Data and experience from this project will inform the planning and conduct of a randomized multicenter trial of the effectiveness of STATIN CHOICE in diverse practice settings.

Significance- Patient participation in decision-making resulting in informed treatment decisions, as proposed in this study, will likely lead to improved quality of decision-making, more appropriate use of statins, and improved patient outcomes.


Options:
A: Arm Label: intervention; Type: EXPERIMENTAL; Interventions: Other: Outreach Facilitation implementing elements of the Chronic Care Model | Arm Label: control; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: OTHER; Name: Outreach Facilitation implementing elements of the Chronic Care Model; Assigned to Arm(s): intervention
B: Arm Label: One-on-one counseling; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Lifestyle and medication intervention | Arm Label: Web counseling; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Lifestyle and medication intervention | Intervention Type: BEHAVIORAL; Name: Lifestyle and medication intervention; Assigned to Arm(s): One-on-one counseling, Web counseling
C: Arm Label: Health check; Type: EXPERIMENTAL; Interventions: Other: Health check | Arm Label: No invitation; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: OTHER; Name: Health check; Assigned to Arm(s): Health check
D: Intervention Type: DEVICE; Name: Decision Aid Statin Choice; Assigned to Arm(s): N/A

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: The Statin Choice Decision Aid and Its Effects on Statin Decisions in Patients With Type 2 Diabetes Mellitus. A Clustered Randomized Trial
Brief Summary: Background- Statins are a safe and effective therapy to reduce cardiovascular risk in patients with type 2 diabetes; however some patients are not prescribed statins, others do not take it even after being prescribed, and others stop therapy prematurely. Lack of knowledge or misinformation about statins may be responsible for inadequate statin use.

Objective- To test the hypothesis that a formal, structured decision aid could correct deficiencies in the current decision-making process, increase statin use, and improve outcomes in patients with type 2 diabetes.

Methods - The investigators will develop a decision aid called STATIN CHOICE and will pilot its efficacy in a blinded randomized controlled trial enrolling 98 type 2 diabetes patients.

Outcomes- Primary outcomes: adherence to the decision to use or not to use statins three months after using STATIN CHOICE. Secondary outcomes: acceptability of STATIN CHOICE, knowledge about options, satisfaction with decisions, decisional conflict, encounter duration, and quality of life.

Expected results- The investigators anticipate that this work will yield an effective and innovative decision aid for statin use in type 2 diabetes patients. STATIN CHOICE, along with a detailed users manual, will be directly applicable in clinical practice. Data and experience from this project will inform the planning and conduct of a randomized multicenter trial of the effectiveness of STATIN CHOICE in diverse practice settings.

Significance- Patient participation in decision-making resulting in informed treatment decisions, as proposed in this study, will likely lead to improved quality of decision-making, more appropriate use of statins, and improved patient outcomes.


Options:
A: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Other: Full drug coverage | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Other: Usual coverage | Intervention Type: OTHER; Name: Full drug coverage; Assigned to Arm(s): 1 | Intervention Type: OTHER; Name: Usual coverage; Assigned to Arm(s): 2
B: Arm Label: polypill; Type: EXPERIMENTAL; Interventions: Drug: polypill | Arm Label: Usual Care; Type: ACTIVE_COMPARATOR; Interventions: Drug: Usual cardiovascular medications | Intervention Type: DRUG; Name: polypill; Assigned to Arm(s): polypill | Intervention Type: DRUG; Name: Usual cardiovascular medications; Assigned to Arm(s): Usual Care
C: Arm Label: FDC Fixed Dose Combination; Type: EXPERIMENTAL; Interventions: Drug: FDC | Arm Label: Conventional treatment; Type: ACTIVE_COMPARATOR; Interventions: Drug: Separately drugs, simvastatin, aspirin and ramipril | Intervention Type: DRUG; Name: FDC; Assigned to Arm(s): FDC Fixed Dose Combination | Intervention Type: DRUG; Name: Separately drugs, simvastatin, aspirin and ramipril; Assigned to Arm(s): Conventional treatment
D: Intervention Type: DEVICE; Name: Decision Aid Statin Choice; Assigned to Arm(s): N/A

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: The Statin Choice Decision Aid and Its Effects on Statin Decisions in Patients With Type 2 Diabetes Mellitus. A Clustered Randomized Trial
Brief Summary: Background- Statins are a safe and effective therapy to reduce cardiovascular risk in patients with type 2 diabetes; however some patients are not prescribed statins, others do not take it even after being prescribed, and others stop therapy prematurely. Lack of knowledge or misinformation about statins may be responsible for inadequate statin use.

Objective- To test the hypothesis that a formal, structured decision aid could correct deficiencies in the current decision-making process, increase statin use, and improve outcomes in patients with type 2 diabetes.

Methods - The investigators will develop a decision aid called STATIN CHOICE and will pilot its efficacy in a blinded randomized controlled trial enrolling 98 type 2 diabetes patients.

Outcomes- Primary outcomes: adherence to the decision to use or not to use statins three months after using STATIN CHOICE. Secondary outcomes: acceptability of STATIN CHOICE, knowledge about options, satisfaction with decisions, decisional conflict, encounter duration, and quality of life.

Expected results- The investigators anticipate that this work will yield an effective and innovative decision aid for statin use in type 2 diabetes patients. STATIN CHOICE, along with a detailed users manual, will be directly applicable in clinical practice. Data and experience from this project will inform the planning and conduct of a randomized multicenter trial of the effectiveness of STATIN CHOICE in diverse practice settings.

Significance- Patient participation in decision-making resulting in informed treatment decisions, as proposed in this study, will likely lead to improved quality of decision-making, more appropriate use of statins, and improved patient outcomes.


Options:
A: Intervention Type: DEVICE; Name: Decision Aid Statin Choice; Assigned to Arm(s): N/A
B: Arm Label: Decision aid; Type: ACTIVE_COMPARATOR; Interventions: Other: Decision Aid | Arm Label: Normal care; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: OTHER; Name: Decision Aid; Assigned to Arm(s): Decision aid
C: Arm Label: Diabetes Medication Choice decision aid; Type: EXPERIMENTAL; Interventions: Behavioral: Diabetes Medication Choice decision aid | Arm Label: Usual Care; Type: OTHER; Interventions: Behavioral: Usual Care | Intervention Type: BEHAVIORAL; Name: Diabetes Medication Choice decision aid; Assigned to Arm(s): Diabetes Medication Choice decision aid | Intervention Type: BEHAVIORAL; Name: Usual Care; Assigned to Arm(s): Usual Care
D: Arm Label: PCI Choice decision; Type: ACTIVE_COMPARATOR; Interventions: Other: Decision Aid | Arm Label: Usual Care; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: OTHER; Name: Decision Aid; Assigned to Arm(s): PCI Choice decision

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: N/A
Brief Summary: To evaluate a model of shared decision-making for asthma treatment, appropriate to the needs of African American, Latino, Chinese, and other Asian and low income Caucasian patients to adherence to asthma controller medications in a two-year randomized clinical trial in 302 minority and low-income adults, 18-70 years of age, with suboptimally controlled, persistent asthma, paralleling a simultaneous evaluation being conducted in 311 Caucasian and Asian/Pacific Island adults, (total n=613), and to examine psychological mechanisms mediating the effects of the intervention on adherence and of adherence on asthma outcomes.


Options:
A: Intervention Type: BEHAVIORAL; Name: Shared Decision-Making; Assigned to Arm(s): N/A
B: Intervention Type: BEHAVIORAL; Name: Shared-Decision Making; Assigned to Arm(s): N/A
C: Intervention Type: BEHAVIORAL; Name: Tailored web-based walking program; Assigned to Arm(s): N/A
D: Arm Label: Group Clinic; Type: EXPERIMENTAL; Interventions: Behavioral: Improving outcomes using group clinics for older patients | Arm Label: Uusual Care; Type: PLACEBO_COMPARATOR; Interventions: Behavioral: Standard of Care | Intervention Type: BEHAVIORAL; Name: Improving outcomes using group clinics for older patients; Assigned to Arm(s): Group Clinic | Intervention Type: BEHAVIORAL; Name: Standard of Care; Assigned to Arm(s): Uusual Care

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: N/A
Brief Summary: To evaluate a model of shared decision-making for asthma treatment, appropriate to the needs of African American, Latino, Chinese, and other Asian and low income Caucasian patients to adherence to asthma controller medications in a two-year randomized clinical trial in 302 minority and low-income adults, 18-70 years of age, with suboptimally controlled, persistent asthma, paralleling a simultaneous evaluation being conducted in 311 Caucasian and Asian/Pacific Island adults, (total n=613), and to examine psychological mechanisms mediating the effects of the intervention on adherence and of adherence on asthma outcomes.


Options:
A: Intervention Type: BEHAVIORAL; Name: Shared-Decision Making; Assigned to Arm(s): N/A
B: Intervention Type: BEHAVIORAL; Name: Disease Management; Assigned to Arm(s): N/A | Intervention Type: BEHAVIORAL; Name: Disease Management + Educational Home Visits; Assigned to Arm(s): N/A
C: Intervention Type: BEHAVIORAL; Name: Shared Decision-Making; Assigned to Arm(s): N/A
D: Arm Label: Integrative Medicine; Type: EXPERIMENTAL; Interventions: Behavioral: Integrative Medicine | Arm Label: Control; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Integrative Medicine; Assigned to Arm(s): Integrative Medicine

Answer: A